 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- M701 / YZY Biopharma
An anti-EpCAM x anti-CD3 bispecific antibody, M701, for the treatment of malignant ascites due to epithelial cancer: Interim results of a prospective randomized controlled phase II trial. (Hall A; Poster Bd #: 189) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2810;
Epithelial cancer patients with MA who received M701 treatment had longer PuFS and OS. These results are promising and support the pivotal trial of M701 as a novel treatment for MA.
- |||| M701 / YZY Biopharma
New P1/2 trial: A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC (clinicaltrials.gov) - Sep 16, 2022
P1/2, N=96, Not yet recruiting, Sponsor: Wuhan YZY Biopharma Co., Ltd.
- M701 / CSPC Pharma
[VIRTUAL] Interim results of a phase I study of M701, a recombinant anti-EpCAM and anti-CD3 bispecific antibody in EpCAM-positive cancer patients with malignant ascites () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1893;
P1
OS showed an improved trend in pts with gastric and ovarian cancer. These interim data support further development of M701 for pts with malignant ascites.
- | M701 / CSPC Pharma
New P1 trial: A Study of M701 (EpCAM and CD3) in Malignant Ascites (clinicaltrials.gov) - Aug 6, 2020
P1, N=42, Recruiting, Sponsor: Wuhan YZY Biopharma Co., Ltd.